Cargando…

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab

Although nivolumab, a programmed cell death 1 (PD‐1) inhibitor, is a standard therapy for platinum‐refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), no definitive biomarkers have been reported thus far. This study aimed to select promising prognostic markers in ni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishikawa, Daisuke, Suzuki, Hidenori, Beppu, Shintaro, Terada, Hoshino, Sawabe, Michi, Kadowaki, Shigenori, Sone, Michihiko, Hanai, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780035/ https://www.ncbi.nlm.nih.gov/pubmed/33078505 http://dx.doi.org/10.1111/cas.14706

Ejemplares similares

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Lymph Node Ratio in Head and Neck Cancer with Submental Flap Reconstruction
por: Suzuki, Hidenori, et al.
Publicado: (2022)

Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma
por: Hagiwara, Sumitaka, et al.
Publicado: (2021)

Safety and Efficacy of Salvage Neck Dissection Following Carbon-ion Radiotherapy with Chemotherapy for a Patient with Mucosal Malignant Melanoma of Head and Neck
por: Suzuki, Hidenori, et al.
Publicado: (2020)

Lymph node ratio as a predictor for minor salivary gland cancer in head and neck
por: Suzuki, Hidenori, et al.
Publicado: (2021)

Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer
por: Nishikawa, Daisuke, et al.
Publicado: (2022)

Metabolic Tumour Volume as a Predictor of Survival for Sinonasal Tract Squamous Cell Carcinoma
por: Suzuki, Hidenori, et al.
Publicado: (2022)

Total lesion glycolysis as a predictor of clinical T3–4a laryngeal cancer with laryngectomy or nonlaryngectomy
por: Suzuki, Hidenori, et al.
Publicado: (2021)

Impact of age for overall survival in head and neck sarcoma
por: Suzuki, Hidenori, et al.
Publicado: (2023)

The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Terada, Hoshino, et al.
Publicado: (2021)

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer
por: Hanai, Nobuhiro, et al.
Publicado: (2018)

The Heterogeneous Impact of Prediagnostic Folate Intake for Fluorouracil-Containing Induction Chemotherapy for Head and Neck Cancer
por: Sawabe, Michi, et al.
Publicado: (2023)

Pathological tumor volume predicts survival outcomes in oral squamous cell carcinoma
por: Mukoyama, Nobuaki, et al.
Publicado: (2018)

Association between treatment package time and clinical predictors in oropharyngeal cancer
por: Suzuki, Hidenori, et al.
Publicado: (2020)

Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Lymph node density in papillary thyroid carcinoma is a prognostic factor after adjusting for pathological stage
por: Suzuki, Hidenori, et al.
Publicado: (2018)

Recurrent ameloblastoma with both hypercalcemia and BRAF mutation: A case report
por: Suzuki, Hidenori, et al.
Publicado: (2020)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients
por: Matsuki, Takashi, et al.
Publicado: (2020)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Current topics and management of head and neck sarcomas
por: Kobayashi, Kenya, et al.
Publicado: (2023)

Heterogeneous impact of alcohol consumption according to treatment method on survival in head and neck cancer: A prospective study
por: Sawabe, Michi, et al.
Publicado: (2017)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Role of Human Papilloma Virus and Lifestyle Factors in Overall Survival of Patients with Oropharyngeal Squamous Cell Carcinoma
por: Nishikawa, Daisuke, et al.
Publicado: (2022)

Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer
por: Kimura, Takahiro, et al.
Publicado: (2018)

Predictive factors for dissection-free sentinel node micrometastases in early oral squamous cell carcinoma
por: Matsuzuka, Takashi, et al.
Publicado: (2023)

Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
por: Luginbuhl, Adam J., et al.
Publicado: (2022)

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
por: Pareek, Ananya, et al.
Publicado: (2021)

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2020)

Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2021)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report
por: Bonomo, Pierluigi, et al.
Publicado: (2020)

Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma
por: Tada, Hiroe, et al.
Publicado: (2020)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2022)

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
por: Johnson, Jennifer M, et al.
Publicado: (2023)

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
por: Yen, Chia‐Jui, et al.
Publicado: (2020)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
por: Tahara, Makoto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_poalftmcd6t8qhnnvehb4pllvp